COMP <GO>
ALNY vs ROIV // NET PROFIT MARGIN
Alnylam Pharmaceuticals Inc. (NASDAQ) VS. Roivant Sciences Ltd. (NASDAQ) • 15-METRIC TALLY: ALNY 6
— ROIV 4
▲ NET PROFIT MARGIN LEADER: ALNY
LAST: $158.00 (-4.24%) • MKT CAP: $22.10B
net-margins
8.40%
LAST: $35.89 (-2.76%) • MKT CAP: $26.66B
net-margins
-60.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ALNY VS. ROIV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ALNY | ROIV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 81.80% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 21.30% | -14.00% | +35.30 | ALNY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 42.4x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 2.00% | -2.80% | +4.80 | ALNY | /fcf-yield <GO> |
| Operating Margin | 13.50% | -60.00% | +73.50 | ALNY | /operating-margins <GO> |
| Net Profit Margin ACTIVE | 8.40% | -60.00% | +68.40 | ALNY | /net-margins <GO> |
| Revenue Growth (YoY) | 65.20% | -65.00% | +130.20 | ALNY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.16 | 26.00 | -22.84 | ROIV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 3/9 | +5.00 | ALNY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 25.8 | 53.3 | -27.50 | ROIV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | 1.00 | 0.00 | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 62.3x | 28.0x | +34.30 | ROIV | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $22.10B | $26.66B | -$4.56B | ROIV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ALNY REV | ROIV REV | ALNY GROSS % | ROIV GROSS % | ALNY FCF | ROIV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.71B | $8.3M | 81.8% | — | $465.4M | -$758.6M |
| FY 2024 | $2.25B | $29.1M | 86.4% | — | -$42.6M | -$844.0M |
| FY 2023 | $1.83B | $32.7M | — | — | $21.9M | -$766.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ALNY // BETA 1.00
ROIV // BETA 1.00